ProFACT seeks to form collaborations with cancer therapeutics and biomarker developers, offering an advantaged Proteomic Profiling platform at an early stage of commercialization. Collaborations can be flexibly structured as partnerships or joint ventures with research institutions and Biopharmaceutical companies.